A detailed summary ofBad Bloodby John Carreyrou

And Carreyrou's answer isn't one big trick. It's a pattern that repeats for over a decade: a promise made in public, a machine that can't deliver it in private, and a culture built to stop anyone from saying so out loud.

That a small device could run hundreds of blood tests using just a few drops from a finger prick, and send results wirelessly in real time. But as Carreyrou tells it, Holmes insisted on using tiny blood samples before her engineers knew how to make that work. There simply wasn't enough blood for many of the tests. Diluting samples created new problems with accuracy. And the early cartridges leaked, cross-contaminated samples, and cost over two hundred dollars each.

That connects to another book, The Lean Startup by Eric Ries. His central idea is that startups should test their assumptions early and let the evidence guide what they build. Theranos did almost the opposite. Holmes committed to a vision before knowing whether the science could support it.

Exactly. And when that system failed, a separate team built something more practical: a miniaturized robot based on a cheap glue-dispensing arm. Holmes named it the Edison. It was more reliable, but it could only perform a limited range of tests. Theranos was promising an entire laboratory in a little box, but its actual machine could do only a fraction of that.

Yes, 2006. Holmes reportedly wowed the pharmaceutical giant Novartis with a live demonstration. But Theranos's chief financial officer, Henry Mosley, later learned that one of the devices had malfunctioned. To hide the problem, the team in California had sent over a fake result. When Mosley confronted Holmes about misleading investors, she fired him on the spot.

Exactly. And that's what makes this episode so revealing. The people at the top knew the technology couldn't consistently do what they were promising. Yet Theranos managed to keep that gap hidden for years.

By making sure nobody could see the whole picture. Holmes kept the engineering and chemistry teams siloed, so an engineer like Ed Ku couldn't always tell whether a failure came from the hardware or the chemistry. IT staff monitored employee emails. Departing employees sometimes had damaging files compiled on them. And when Sunny Balwani came in as her second in command, he checked badge records and fired people in front of colleagues.

It used the same justification, protecting trade secrets, but Carreyrou shows how that secrecy also prevented people from checking whether the technology worked. Take Kevin Hunter, the lab consultant Walgreens hired in 2010 to evaluate the deal. He asked to see the lab. Refused. He asked for a simple side-by-side test, Theranos against a standard lab. Refused. Eventually Holmes and Balwani had him removed from meetings entirely.

Right. There's a difference between protecting your technology from competitors and preventing the people who depend on it from finding out whether it works. At Theranos, even the experts hired to verify the claims couldn't get a straight answer.

Carreyrou's explanation is borrowed credibility. Theranos had a board full of famous names: George Shultz, Henry Kissinger, General Mattis. Investors assumed somebody else must have checked the technology. Walgreens was afraid CVS would get the deal first, so it brushed aside its own consultant's warnings. Safeway spent hundreds of millions remodeling stores for testing centers that never opened. And Rupert Murdoch invested a hundred twenty-five million dollars after meeting Holmes and hearing glowing references.

In the book Influence, Robert Cialdini describes social proof: the less sure people are, the more they look to what others are doing to decide what's correct. One way to read the Theranos board is that it served as exactly that kind of crowd.

And even when investors did ask for evidence, they couldn't necessarily trust what they received. One hedge fund that invested ninety-six million dollars was shown accuracy data from conventional lab machines, not Theranos's own devices. It also received revenue projections that were five to twelve times higher than the company's internal forecasts.

He draws an important distinction. Silicon Valley celebrates the idea of fake it till you make it. Holmes embraced that culture, dressing like Steve Jobs, hiring Apple's ad agency, and selling a vision of revolutionary technology. But Theranos wasn't building another software app. It was testing people's blood. If an app doesn't work, users get frustrated. If a blood test doesn't work, a patient might receive the wrong diagnosis.

September 2013. Theranos launched its testing service in Walgreens stores, even though its new machine, the miniLab, still wasn't ready. So Holmes and Balwani used the older Edison machines for the handful of tests they could perform. For everything else, they secretly relied on commercial Siemens analyzers, modifying them to work with diluted blood from finger pricks. Customers believed they were getting revolutionary Theranos technology, but much of the testing was happening on ordinary lab equipment.

They do, but only when the tests are designed and validated for it. These Siemens machines were built to work with larger blood samples, usually drawn from a vein. Theranos was diluting tiny finger-prick samples to make them usable, potentially magnifying errors and making results unreliable. One chemist, Anjali Laghari, had years of data showing the Edison's error rates were unacceptable. She warned management, was ignored, and resigned. At the next all-hands meeting, Holmes declared that she was building a religion, and anyone who wasn't fully devoted should leave.

It is. And patients were already paying the price. Blood samples overheated during shipping. Some patients received potassium readings so dangerously high they would have suggested a medical emergency. Carreyrou had his own blood tested at Theranos and a conventional lab and found serious discrepancies. One doctor received a cortisol result from Theranos that suggested a life-threatening problem, while another lab found it completely normal. Theranos eventually had to void nearly a million test results.

It does, through Tyler Shultz. He was George Shultz's grandson, fresh out of Stanford, working on a team that checked whether the Edison machines produced accurate results. He watched failed tests get thrown out and repeated until the numbers looked better. On one syphilis test, the machines detected only about sixty-five to eighty percent of positive cases, but the official report claimed ninety-five percent. He also discovered Theranos was using commercial lab machines for federally required proficiency testing, essentially hiding how poorly its own devices performed.

He did, and he emailed Holmes a detailed list of concerns. But the response came from Balwani, attacking him and demanding an apology. Even his grandfather sided with the company. Later, after Tyler spoke to Carreyrou, two lawyers confronted him at his grandfather's house with legal papers. He was followed by private investigators, and his family faced the threat of financial ruin from legal costs. Another employee, Erika Cheung, received a threatening legal letter in a parking lot. Theranos was making it very expensive to tell the truth.

They found ways to get the evidence outside the company. Tyler preserved emails and documents that supported his concerns. Both sought independent legal advice rather than relying on Theranos's lawyers. And Erika filed a detailed complaint with federal regulators about the laboratory's practices. Her warnings helped expose problems that regulators could investigate independently. They weren't just making accusations. They were giving outsiders something concrete to verify.

A lot. Theranos's lawyer, David Boies, showed up at the Wall Street Journal with tape recorders and later sent a twenty-three-page legal threat. Holmes personally appealed to Rupert Murdoch, who owned the Journal's parent company, to stop the investigation. He refused to interfere. Carreyrou's first exposé appeared in October 2015, revealing that Theranos relied heavily on conventional laboratory equipment rather than its supposedly revolutionary machines. Regulators were also uncovering serious problems. Subsequent investigations exposed unreliable testing, quality-control failures, and misleading claims about what the technology could do.

She publicly denied the allegations. Balwani even led employees in a profane chant against Carreyrou. But the evidence kept mounting. Regulators shut down the labs, Walgreens ended its partnership and sued, and in March 2018, the SEC charged Theranos, Holmes, and Balwani with fraud. Holmes settled the civil charges and gave up control of the company. That's where the book's main account ends.

No. Holmes had deliberately structured the company so she held nearly all the voting power. She was also the one selling the vision to investors, partners, and powerful board members. Carreyrou stops short of diagnosing her as a sociopath, but portrays someone whose ambition became more important than the truth, even when patients were at risk. Holmes declined to cooperate with the book, so her perspective comes largely through documents and other people's accounts.

That's the central lesson. And there's another warning sign: watch what happens to the people who ask hard questions. At Theranos, scientists and engineers repeatedly raised concerns, only to be ignored, pushed out, or threatened. Meanwhile, the powerful outsiders who praised the company often hadn't seen the evidence themselves.

No. A board full of famous names tells you who was charmed. Only the data tells you whether the machine works.